EVA1B (eva-1 homolog B) is a protein-coding gene located on chromosome 1 with demonstrated roles as a prognostic biomarker across multiple cancer types. Primary Function and Mechanism: EVA1B functions through protein binding interactions 1 and appears to regulate cancer cell behavior through multiple pathways. In esophageal squamous carcinoma, EVA1B suppression reduces proliferation, induces apoptosis, and impairs cell aggressiveness through modulation of the Wnt/β-catenin signaling pathway (via Wnt3a, β-catenin, and LRP6 expression) 2. Disease Relevance: EVA1B is consistently upregulated across multiple cancer types, including breast cancer, colorectal cancer, esophageal squamous carcinoma, and glioma 1324. High EVA1B expression correlates with advanced tumor stages, poor prognosis, and enhanced immune cell infiltration 324. In esophageal cancer, EVA1B overexpression promotes recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs) through increased expression of expansion stimulators (S100A8, S100A9, Arg-1, and VEGF) 2. Clinical Significance: EVA1B functions as an independent prognostic biomarker superior to traditional immune markers like PD-L1 for predicting immune infiltration in glioma 4. Integration into multi-gene prognostic models demonstrates utility for predicting patient survival and drug sensitivity across breast and colorectal cancers 135.